Implicity has banked €35M to grow its AI monitoring of patients with pacemakers and implanted defibrillators. IRIS led the financing and Five Arrows joined as co-investor. Part of the money will fund acquisitions plus fresh commercial teams in the US and Germany.
Founder and chief executive Arnaud Rosier still works part-time as an electrophysiologist. He started the company after watching cardiac devices generate more alerts than clinics could handle, and the platform now pulls data from five device manufacturers plus hospital records into one view.
Two AI products sit on top of that data. Signal HF combines device readings with France’s Health Data Hub to flag patients at risk of hospitalization and won FDA clearance roughly two years ago. A second tool filters out false alarms by weighing medication history and clinical context, cutting the noise that overwhelms monitoring staff.
Rosier draws a line between his company and US rivals such as Murj and PaceMate, which he says help clinics sort device data without building medical AI of their own. He also sees a wide runway: industry figures cited by Implicity put remote cardiac monitoring at about $4.1B in 2024 and on course for $12B by 2034.
Around 120 to 125 people work at Implicity, with 15 stationed in the US, and total funding since 2016 stands near $69M. Rosier calls the US a large but difficult market, and the fresh capital will fund a bigger commercial presence there plus potential buyouts of smaller players.
